Ketipinor

Quetiapine, the active ingredient in Ketipinor, is a second‑generation atypical antipsychotic presented as an oral dosage form for oral use. It treats schizophrenia, bipolar disorder (both manic and depressive phases) and is used as an adjunct in major depressive disorder in adults.

GNH USA supplies Ketipinor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is indicated for several psychiatric conditions within the schizophrenia and mood‑disorder spectrum.

- Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations, and thought disorder. - Bipolar disorder (manic episodes): stabilises mood and decreases mania severity. - Bipolar disorder (depressive episodes): alleviates depressive symptoms. - Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Sedation or somnolence. - Dizziness, especially on standing. - Dry mouth. - Constipation. - Weight gain. - Orthostatic hypotension.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Neuroleptic malignant syndrome. - Tardive dyskinesia or other extrapyramidal symptoms. - Emergence of suicidal thoughts or behaviors.

When prescribing Ketipinor, clinicians should consider several safety measures.

- Monitor for sedation: advise patients about driving and operating machinery. - Assess metabolic parameters: check weight, glucose, and lipid levels regularly. - Evaluate for orthostatic hypotension: measure blood pressure on standing. - Review psychiatric history: watch for emergence of suicidal ideation. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal effects. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Quetiapine can interact with a variety of medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy by reducing plasma concentrations. - Other CNS depressants (e.g., alcohol, benzodiazepines): may enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive orthostatic hypotension. - Anticholinergic agents: may worsen dry mouth and constipation. - QT‑prolonging drugs: potential additive cardiac risk.